GARP on hepatic stellate cells is essential for the development of liver fibrosis.
GARP
TGF-β
endothelin-1 (ET-1)
hepatic stellate cells (HSCs)
liver fibrosis
natural killer T (NKT) cells
Journal
Journal of hepatology
ISSN: 1600-0641
Titre abrégé: J Hepatol
Pays: Netherlands
ID NLM: 8503886
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
18
11
2022
revised:
17
05
2023
accepted:
31
05
2023
pmc-release:
01
11
2024
pubmed:
23
6
2023
medline:
23
6
2023
entrez:
22
6
2023
Statut:
ppublish
Résumé
Glycoprotein A repetitions predominant (GARP) is a membrane protein that functions as a latent TGF-β docking molecule. While the immune regulatory properties of GARP on blood cells have been studied, the function of GARP on tissue stromal cells remains unclear. Here, we investigate the role of GARP expressed on hepatic stellate cells (HSCs) in the development of liver fibrosis. The function of GARP on HSCs was explored in toxin-induced and metabolic liver fibrosis models, using conditional GARP-deficient mice or a newly generated inducible system for HSC-specific gene ablation. Primary mouse and human HSCs were isolated to evaluate the contribution of GARP to the activation of latent TGF-β. Moreover, cell contraction of HSCs in the context of TGF-β activation was tested in a GARP-dependent fashion. Mice lacking GARP in HSCs were protected from developing liver fibrosis. Therapeutically deleting GARP on HSCs alleviated the fibrotic process in established disease. Furthermore, natural killer T cells exacerbated hepatic fibrosis by inducing GARP expression on HSCs through IL-4 production. Mechanistically, GARP facilitated fibrogenesis by activating TGF-β and enhancing endothelin-1-mediated HSC contraction. Functional GARP was expressed on human HSCs and significantly upregulated in the livers of patients with fibrosis. Lastly, deletion of GARP on HSCs did not augment inflammation or liver damage. GARP expressed on HSCs drives the development of liver fibrosis via cell contraction-mediated activation of latent TGF-β. Considering that systemic blockade of TGF-β has major side effects, we highlight a therapeutic niche provided by GARP and surface-mediated TGF-β activation. Thus, our findings suggest an important role of GARP on HSCs as a promising target for the treatment of liver fibrosis. Liver fibrosis represents a substantial and increasing public health burden globally, for which specific treatments are not available. Glycoprotein A repetitions predominant (GARP) is a membrane protein that functions as a latent TGF-β docking molecule. Here, we show that GARP expressed on hepatic stellate cells drives the development of liver fibrosis. Our findings suggest GARP as a novel target for the treatment of fibrotic disease.
Sections du résumé
BACKGROUND & AIMS
OBJECTIVE
Glycoprotein A repetitions predominant (GARP) is a membrane protein that functions as a latent TGF-β docking molecule. While the immune regulatory properties of GARP on blood cells have been studied, the function of GARP on tissue stromal cells remains unclear. Here, we investigate the role of GARP expressed on hepatic stellate cells (HSCs) in the development of liver fibrosis.
METHODS
METHODS
The function of GARP on HSCs was explored in toxin-induced and metabolic liver fibrosis models, using conditional GARP-deficient mice or a newly generated inducible system for HSC-specific gene ablation. Primary mouse and human HSCs were isolated to evaluate the contribution of GARP to the activation of latent TGF-β. Moreover, cell contraction of HSCs in the context of TGF-β activation was tested in a GARP-dependent fashion.
RESULTS
RESULTS
Mice lacking GARP in HSCs were protected from developing liver fibrosis. Therapeutically deleting GARP on HSCs alleviated the fibrotic process in established disease. Furthermore, natural killer T cells exacerbated hepatic fibrosis by inducing GARP expression on HSCs through IL-4 production. Mechanistically, GARP facilitated fibrogenesis by activating TGF-β and enhancing endothelin-1-mediated HSC contraction. Functional GARP was expressed on human HSCs and significantly upregulated in the livers of patients with fibrosis. Lastly, deletion of GARP on HSCs did not augment inflammation or liver damage.
CONCLUSIONS
CONCLUSIONS
GARP expressed on HSCs drives the development of liver fibrosis via cell contraction-mediated activation of latent TGF-β. Considering that systemic blockade of TGF-β has major side effects, we highlight a therapeutic niche provided by GARP and surface-mediated TGF-β activation. Thus, our findings suggest an important role of GARP on HSCs as a promising target for the treatment of liver fibrosis.
IMPACT AND IMPLICATIONS
UNASSIGNED
Liver fibrosis represents a substantial and increasing public health burden globally, for which specific treatments are not available. Glycoprotein A repetitions predominant (GARP) is a membrane protein that functions as a latent TGF-β docking molecule. Here, we show that GARP expressed on hepatic stellate cells drives the development of liver fibrosis. Our findings suggest GARP as a novel target for the treatment of fibrotic disease.
Identifiants
pubmed: 37348791
pii: S0168-8278(23)00422-1
doi: 10.1016/j.jhep.2023.05.043
pmc: PMC10592496
mid: NIHMS1910256
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1214-1225Subventions
Organisme : NIAID NIH HHS
ID : R01 AI083426
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI136939
Pays : United States
Informations de copyright
Copyright © 2023 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Références
Mol Biol Cell. 2012 Mar;23(6):1129-39
pubmed: 22278742
J Immunol. 2013 May 15;190(10):5226-36
pubmed: 23596313
Biochem Biophys Res Commun. 1995 Feb 15;207(2):725-31
pubmed: 7864865
Blood. 2023 Feb 2;141(5):490-502
pubmed: 36322928
Gastroenterology. 2020 May;158(7):1913-1928
pubmed: 32044315
Mol Biosyst. 2017 Sep 26;13(10):1925-1935
pubmed: 28795730
Cancer Res. 2019 Mar 15;79(6):1178-1190
pubmed: 30674536
J Biol Chem. 1999 Jan 29;274(5):3228-34
pubmed: 9915864
Hepatology. 2010 Jun;51(6):1998-2007
pubmed: 20512988
J Clin Invest. 2017 Jan 3;127(1):55-64
pubmed: 28045404
Nat Rev Gastroenterol Hepatol. 2021 Mar;18(3):151-166
pubmed: 33128017
Hepatology. 2015 May;61(5):1547-54
pubmed: 25125077
Cold Spring Harb Perspect Biol. 2017 Oct 3;9(10):
pubmed: 28246179
JCI Insight. 2017 Jul 6;2(13):
pubmed: 28679947
Nat Commun. 2013;4:2823
pubmed: 24264436
Cancer Chemother Pharmacol. 2017 Apr;79(4):673-680
pubmed: 28280971
Nature. 2011 Jun 15;474(7351):343-9
pubmed: 21677751
J Clin Invest. 1996 Sep 15;98(6):1381-8
pubmed: 8823303
Sci Rep. 2017 Mar 06;7:43446
pubmed: 28262670
Gastroenterology. 2006 Feb;130(2):435-52
pubmed: 16472598
Gut. 2012 Sep;61(9):1323-9
pubmed: 22427237
Physiol Rev. 2008 Jan;88(1):125-72
pubmed: 18195085
Gastroenterology. 1996 Feb;110(2):534-48
pubmed: 8566602
J Immunol. 2013 Jun 1;190(11):5506-15
pubmed: 23645881
J Hepatol. 2000 Jan;32(1):43-50
pubmed: 10673066
Immunity. 2017 Oct 17;47(4):752-765.e5
pubmed: 29045904
Am J Med Sci. 2015 Jan;349(1):6-16
pubmed: 25559279
Proc Natl Acad Sci U S A. 2009 Aug 11;106(32):13439-44
pubmed: 19666573
JCI Insight. 2018 Apr 5;3(7):
pubmed: 29618665
Lancet Gastroenterol Hepatol. 2020 Mar;5(3):245-266
pubmed: 31981519
Mol Med. 2009 Mar-Apr;15(3-4):85-94
pubmed: 19098997
Nat Rev Gastroenterol Hepatol. 2017 Jul;14(7):397-411
pubmed: 28487545
Nat Rev Immunol. 2018 Sep;18(9):559-574
pubmed: 29967365
J Hematol Oncol. 2018 Feb 20;11(1):24
pubmed: 29458436
Nature. 2001 Oct 4;413(6855):531-4
pubmed: 11586362
Cell Mol Immunol. 2021 Jan;18(1):45-56
pubmed: 33041338
Sci Immunol. 2017 May 5;2(11):
pubmed: 28763790
Eur J Immunol. 2016 Jun;46(6):1480-9
pubmed: 27062243
Hepatology. 1998 Sep;28(3):655-9
pubmed: 9731554
J Immunol. 2018 Nov 15;201(10):3017-3035
pubmed: 30322964
Curr Biol. 2011 Dec 20;21(24):2046-54
pubmed: 22169532
Cold Spring Harb Perspect Biol. 2016 Jun 01;8(6):
pubmed: 27252363
PLoS One. 2008 Jul 16;3(7):e2705
pubmed: 18628982
Proc Natl Acad Sci U S A. 2009 Aug 11;106(32):13445-50
pubmed: 19651619
Sci Transl Med. 2015 Apr 22;7(284):284ra56
pubmed: 25904740
Nat Med. 2013 Dec;19(12):1617-24
pubmed: 24216753
Science. 2018 Nov 23;362(6417):952-956
pubmed: 30361387
J Hepatol. 2006 Jul;45(1):60-71
pubmed: 16515819
J Clin Invest. 2004 Jun;113(11):1631-40
pubmed: 15173890
J Immunol. 2015 Sep 15;195(6):2648-56
pubmed: 26246140